Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Keytruda in advanced hepatocellular carcinoma
NCT02702401Phase 3Completed
- Sponsor
- Merck & Co.
- Start
- May 2016
- Primary completion
- Jan 2019
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes
01
Overview
Phase 3, randomised, double-blind trial of pembrolizumab in hepatocellular carcinoma (HCC), sponsored by Merck & Co. Started May 2016; status: completed.
02
Drugs
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT02702401.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02702401.